PT2007391E - Combinação compreendendo: a) um composto de pirimidil-aminobenzamida e b) um inibidor da cinase thr315ile - Google Patents

Combinação compreendendo: a) um composto de pirimidil-aminobenzamida e b) um inibidor da cinase thr315ile

Info

Publication number
PT2007391E
PT2007391E PT77278810T PT07727881T PT2007391E PT 2007391 E PT2007391 E PT 2007391E PT 77278810 T PT77278810 T PT 77278810T PT 07727881 T PT07727881 T PT 07727881T PT 2007391 E PT2007391 E PT 2007391E
Authority
PT
Portugal
Prior art keywords
thr315lle
combination
kinase inhibitor
pyrimidylaminobenzamide compound
pyrimidylaminobenzamide
Prior art date
Application number
PT77278810T
Other languages
English (en)
Inventor
Paul W Manley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2007391E publication Critical patent/PT2007391E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT77278810T 2006-04-07 2007-04-05 Combinação compreendendo: a) um composto de pirimidil-aminobenzamida e b) um inibidor da cinase thr315ile PT2007391E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79043806P 2006-04-07 2006-04-07
US79115006P 2006-04-11 2006-04-11

Publications (1)

Publication Number Publication Date
PT2007391E true PT2007391E (pt) 2013-03-11

Family

ID=38229305

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77278810T PT2007391E (pt) 2006-04-07 2007-04-05 Combinação compreendendo: a) um composto de pirimidil-aminobenzamida e b) um inibidor da cinase thr315ile

Country Status (13)

Country Link
US (1) US20090286803A1 (pt)
EP (2) EP2574340A3 (pt)
JP (2) JP2009532440A (pt)
KR (1) KR20090023561A (pt)
AU (1) AU2007235900A1 (pt)
BR (1) BRPI0710496A2 (pt)
CA (1) CA2647803C (pt)
ES (1) ES2400375T3 (pt)
MX (1) MX2008012971A (pt)
PL (1) PL2007391T3 (pt)
PT (1) PT2007391E (pt)
RU (2) RU2481840C2 (pt)
WO (1) WO2007116029A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0810028A2 (pt) * 2007-04-17 2014-10-21 Novartis Ag Éteres de amidas de ácido naftaleno carboxílico no tratamento de câncer
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
JP2013509444A (ja) * 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
CN102822141A (zh) * 2010-01-20 2012-12-12 普罗诺瓦生物医药挪威公司 水杨酸脂肪酸衍生物
CN109730996B (zh) * 2017-03-01 2021-08-24 浙江大学 喹啉结构类型雄激素受体拮抗剂及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156368A0 (en) 2000-12-21 2004-01-04 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same
CA2459822C (en) * 2001-09-05 2013-01-29 Jean-Pierre Robin Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
WO2003047523A2 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
FR2841116B1 (fr) 2002-06-19 2004-11-26 Seb Sa Cafetiere du type expresso a reservoir d'eau amovible
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004026234A2 (en) * 2002-09-19 2004-04-01 University Of South Florida Method of treating leukemia with a combination of suberoylanilide hydromaxic acid and imatinib mesylate
DE10330916A1 (de) 2003-07-04 2005-02-03 Pilz Gmbh & Co. Kg Vorrichtung und Verfahren zum automatisierten Steuern eines Betriebsablaufs bei einer technischen Anlage
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1758892B1 (en) 2004-06-10 2012-10-17 Irm Llc Compounds and compositions as protein kinase inhibitors
KR20070050918A (ko) * 2004-07-02 2007-05-16 뉴텍 파마 피엘씨 암의 치료
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
GB0421525D0 (en) * 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations

Also Published As

Publication number Publication date
RU2013103746A (ru) 2014-08-10
ES2400375T8 (es) 2013-09-10
PL2007391T3 (pl) 2013-05-31
ES2400375T3 (es) 2013-04-09
JP2009532440A (ja) 2009-09-10
EP2007391B8 (en) 2013-05-29
KR20090023561A (ko) 2009-03-05
MX2008012971A (es) 2008-10-15
WO2007116029A2 (en) 2007-10-18
CA2647803A1 (en) 2007-10-18
EP2574340A3 (en) 2013-04-17
CA2647803C (en) 2014-05-27
EP2007391A2 (en) 2008-12-31
US20090286803A1 (en) 2009-11-19
JP2013224304A (ja) 2013-10-31
RU2008143704A (ru) 2010-05-20
WO2007116029A3 (en) 2008-12-11
EP2007391B1 (en) 2012-12-19
RU2481840C2 (ru) 2013-05-20
EP2574340A2 (en) 2013-04-03
AU2007235900A1 (en) 2007-10-18
BRPI0710496A2 (pt) 2011-08-16

Similar Documents

Publication Publication Date Title
IL197381A0 (en) Kinase inhibitor
HK1133641A1 (zh) 激酶抑製劑化合物
IL190078A0 (en) Kinase inhibitors
ZA200900109B (en) Pyrrolotriazine kinase inhibitors
EP1794137A4 (en) SPECIFIC KINASE INHIBITORS
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
PL1943243T3 (pl) Inhibitory kinazy
IL183276A0 (en) Kinase inhibitors
HK1100141A1 (en) Kinase inhibitors
TWM299071U (en) Hole saw
IL195331A0 (en) Hsp90 inhibitor
IL188850A0 (en) Cathepsin k inhibitors
PL2007391T3 (pl) Kombinacja zawierająca A) pirymidyloaminobenzamid i B) inhibitor kinazy THR315LLE
EP2038304A4 (en) BST2 INHIBITORS
GB0603522D0 (en) Kinase inhibition
GB0421355D0 (en) Inhibitors
ZA200908943B (en) Pyrazolopyrimidinone kinase inhibitor
IL197981A0 (en) Kinase inhibitors
GB0421356D0 (en) Inhibitors
GB0608854D0 (en) P13 kinase inhibitors
GB0516967D0 (en) Inhibitors
PL1917655T3 (pl) System z korpusem świecącym oraz korpus świecący do systemu z korpusem świecącym
EP2076490A4 (en) INHIBITORS OF CATHEPSIN B
ZA200809814B (en) HSP90 Inhibitor